
In a phase 2 trial, tofacitinib met its safety end point and lowered interferon and cytokine scores in adolescents and adults with Down syndrome.
Some recent studies show the significant effects of Kawasaki disease on coronary arteries. Researchers all agree on the urgent need for early diagnosis and improved treatment therapies.






